Emergency drug use in a pandemic: Harsh lessons from COVID-19

Gail Cross; Jessica S Y Ho; William Zacharias; Anand D Jeyasekharan; Ivan Marazzi

doi:10.1016/j.cell.2021.09.025

Emergency drug use in a pandemic: Harsh lessons from COVID-19

Cell. 2021 Oct 28;184(22):5497-5500. doi: 10.1016/j.cell.2021.09.025. Epub 2021 Sep 21.

Authors

Gail Cross¹, Jessica S Y Ho², William Zacharias³, Anand D Jeyasekharan⁴, Ivan Marazzi⁵

Affiliations

¹ Department of Medicine, National University Hospital, National University of Singapore, Singapore 117599, Singapore. Electronic address: mdcgbc@nus.edu.sg.
² Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
³ Departments of Pediatrics and Medicine, Divisions of Pulmonary Biology and Pulmonary and Critical Care Medicine, University of Cincinnati School of Medicine, Cincinnati Children's Hospital, Cincinnati, OH, USA.
⁴ Department of Medicine, National University Hospital, National University of Singapore, Singapore 117599, Singapore; Department of Haematology-Oncology, National University Hospital and Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599, Singapore. Electronic address: csiadj@nus.edu.sg.
⁵ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: ivan.marazzi@mssm.edu.

Abstract

The scientific and clinical communities have both experienced several harsh lessons on clinical care management and drug development during the COVID-19 pandemic. Here, we discuss several key lessons learned and describe a framework within which our two communities can work together and invest in to improve future pandemic responses.

MeSH terms

COVID-19 Drug Treatment*
Drug Development*
Humans
Pandemics / prevention & control*
Pharmaceutical Preparations

Substances

Pharmaceutical Preparations